1
|
Kenmoe S, Nair H. The disease burden of respiratory syncytial virus in older adults. Curr Opin Infect Dis 2024; 37:129-136. [PMID: 38197402 PMCID: PMC10911257 DOI: 10.1097/qco.0000000000001000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2024]
Abstract
PURPOSE OF REVIEW To highlight the respiratory syncytial virus (RSV) disease burden and the current developments and challenges in RSV prevention for older adults ≥60 years through analysis of RSV epidemiology and the effectiveness of emerging vaccines. RECENT FINDINGS In industrialized countries, RSV incidence rates and hospitalization rates among older adults are estimated to be 600.7 cases per 100 000 person-years and 157 hospitalizations per 100 000 person-years, respectively. Yet, accurately determining RSV morbidity and mortality in older adults is challenging, thus resulting in substantially under-estimating the disease burden. The in-hospital fatality rates vary substantially with age and geographies, and can be as high as 9.1% in developing countries. Two promising RSV vaccines for the elderly have been approved, demonstrating efficacies of up to 94.1%, signifying considerable advancement in RSV prevention. However, concerns over potential side effects remain. SUMMARY RSV is associated with a significant burden in older adults. While the landscape of RSV prevention in older adults is promising with the licensure of vaccines from two companies, current trial data underscore the need for additional studies. Addressing the real-world effectiveness of these vaccines, understanding potential rare side effects, and ensuring broad inclusivity in future trials are crucial steps to maximize their potential benefits.
Collapse
Affiliation(s)
- Sebastien Kenmoe
- Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK
| | - Harish Nair
- Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK
- School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China
- School of Public Health, University of the Witwatersrand, South Africa
| |
Collapse
|
2
|
Guillien A, Niespodziana K, Mauclin M, Boudier A, Varraso R, Leynaert B, Dumas O, Le Moual N, Schlederer T, Bajic M, Borochova K, Errhalt P, Vernet R, Nadif R, Bousquet J, Bouzigon E, Valenta R, Siroux V. Determinants of immunoglobulin G responses to respiratory syncytial virus and rhinovirus in children and adults. Front Immunol 2024; 15:1355214. [PMID: 38500884 PMCID: PMC10945029 DOI: 10.3389/fimmu.2024.1355214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Accepted: 02/05/2024] [Indexed: 03/20/2024] Open
Abstract
Introduction Exposure to respiratory viruses is a significant cause of morbidity and affects virus-specific antibody levels. Little is known about determinants associated with immune response to these viruses. We aimed to investigate the determinants of respiratory syncytial virus (RSV)- and rhinovirus (RV)- specific IgG responses in both children and adults. Methods The study is based on the EGEA cohort, composed of 530 samples of children in EGEA1 (1991-95) and 1241 samples of adults in EGEA2 (2003-07). Cumulative RV-specific IgG levels (species A, B and C) and IgG levels to RSV-G protein were measured by using micro-array technoloy. Multiple linear mixed models (random effect to account for familial dependence) were performed to assess associations between age, sex, body mass index (BMI), tobacco smoke exposure and season of blood sampling with RSV-and RV-specific IgG levels. Results In children (11.1 ± 2.8 years old, 57% boys), higher RV-specific IgG levels were associated with older age (only for RV-B), female sex and lower BMI, while only older age was associated with higher RSV-specific IgG levels. In adults (43.5 ± 16.7 years old, 48% men), younger age, female sex, lower BMI, active smoking and all seasons except summer were associated with higher RV-specific IgG levels. Older age, active smoking and all seasons except summer were associated with higher RSV-specific IgG levels. Conclusion Personal and seasonal determinants of RSV- and RV-specific IgG levels seem to vary according to the respiratory virus type and between children and adults, suggesting different patterns of responses along the life course.
Collapse
Affiliation(s)
- Alicia Guillien
- University Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Team in Environmental Epidemiology Applied to Development and Respiratory Health, Institute for Advanced Biosciences, Grenoble, France
| | - Katarzyna Niespodziana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Marion Mauclin
- University Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Team in Environmental Epidemiology Applied to Development and Respiratory Health, Institute for Advanced Biosciences, Grenoble, France
| | - Anne Boudier
- University Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Team in Environmental Epidemiology Applied to Development and Respiratory Health, Institute for Advanced Biosciences, Grenoble, France
- CHU Grenoble Alpes, Grenoble, France
| | - Raphäelle Varraso
- Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Equipe d’Epidémiologie Respiratoire Intégrative, Centre de recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France
| | - Bénédicte Leynaert
- Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Equipe d’Epidémiologie Respiratoire Intégrative, Centre de recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France
| | - Orianne Dumas
- Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Equipe d’Epidémiologie Respiratoire Intégrative, Centre de recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France
| | - Nicole Le Moual
- Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Equipe d’Epidémiologie Respiratoire Intégrative, Centre de recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France
| | - Thomas Schlederer
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Maja Bajic
- Karl Landsteiner University, Krems, Austria
| | - Kristina Borochova
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Peter Errhalt
- Karl Landsteiner University, Krems, Austria
- Department of Pneumology, University Hospital, Krems, Austria
| | - Raphaël Vernet
- Université Paris Cité, Inserm, UMRS 1124, Group of Genomic Epidemiology of Multifactorial Diseases, Paris, France
| | - Rachel Nadif
- Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Equipe d’Epidémiologie Respiratoire Intégrative, Centre de recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France
| | - Jean Bousquet
- Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Equipe d’Epidémiologie Respiratoire Intégrative, Centre de recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France
| | - Emmanuelle Bouzigon
- Université Paris Cité, Inserm, UMRS 1124, Group of Genomic Epidemiology of Multifactorial Diseases, Paris, France
| | - Rudolf Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
- Karl Landsteiner University, Krems, Austria
| | - Valérie Siroux
- University Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Team in Environmental Epidemiology Applied to Development and Respiratory Health, Institute for Advanced Biosciences, Grenoble, France
| |
Collapse
|